Evidence map›Paper›PMID 38495572›Full record

ArticleArXiv2024

The use of next-generation sequencing in personalized medicine.

Liya Popova, Valerie J Carabetta

Abstract readPreprint
PubMed Full text at PMC
In one paragraph

Article in ArXiv, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Liya PopovaDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden NJ, 08103.
Valerie J CarabettaDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden NJ, 08103.

Funding

Investigation of the physiological significance of protein acetylation in Bacillus subtilisR35GM138303 · NIGMS · ROWAN UNIVERSITY · PI CARABETTA, VALERIE JEAN · 2020 to 2024
$1.9M
NIGMS NIH HHS R35 GM138303
6 · The paper itself

Abstract

The revolutionary progress in development of next-generation sequencing (NGS) technologies has made it possible to deliver accurate genomic information in a timely manner. Over the past several years, NGS has transformed biomedical and clinical research and found its application in the field of personalized medicine. Here we discuss the rise of personalized medicine and the history of NGS. We discuss current applications and uses of NGS in medicine, including infectious diseases, oncology, genomic medicine, and dermatology. We provide a brief discussion of selected studies where NGS was used to respond to wide variety of questions in biomedical research and clinical medicine. Finally, we discuss the challenges of implementing NGS into routine clinical use.

Indexed as

deep sequencingHigh-throughput sequencingmassively parallel sequencingnext-generation sequencingpersonalized medicinesecond generation sequencingultra-high-throughput sequencing

Identifiers

PMID38495572
PMCPMC10942477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.